SCALE 2026: Ipsen Reports Phase 2 Corabotase Data in Glabellar Lines

Ipsen presented late-breaking Phase 2 data for corabotase, its investigational recombinant neuroinhibitor, in moderate-to-severe glabellar lines at the 2026 SCALE Symposium in Nashville, Tennessee.

The study included 183 patients. At week 4, 66% of patients treated with corabotase 50 ng achieved a statistically significant 2-grade or greater composite improvement compared with 0% of patients receiving placebo, meeting the study’s primary endpoint (P = .0001). Dysport-treated patients had a 54.3% composite response at week 4.

Corabotase Duration and Patient Satisfaction Data

At week 24, 60.8% of patients treated with corabotase 50 ng had sustained clinical effect, defined as an investigator-assessed glabellar line severity score of “none” or “mild,” compared with 0.2% with placebo and 36.7% with Dysport. Patient-reported satisfaction was also high, with 82.8% of corabotase 50 ng-treated patients reporting they were “very satisfied” or “satisfied” on the Subject Level of Satisfaction 4-point categorical scale.

Patient-reported data showed onset of action at 0.84 days with corabotase 50 ng. Ipsen reported that corabotase was well tolerated, with no significant safety concerns across evaluated doses in Stage 1, and adverse event frequency was comparable across corabotase, Dysport, and placebo arms.

“First data are encouraging for patients, based on the overall satisfaction results, and I look forward to following the corabotase journey,” said Martina Kerscher, MD, professor of dermatology and head of cosmetic sciences at the University of Hamburg.

Ipsen selected the 50 ng dose for further evaluation in the Phase 3 LAURITE program. The Phase 2 LANTIC trial remains ongoing, with proof-of-concept data expected in forehead lines and lateral canthal lines.

Source

Ipsen. Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction. Presented at: SCALE Symposium 2026; Nashville, TN.